A sub-group analysis showed a trend for improved OS amongst patients with a higher FLT3-ITD allelic ratio (>0.7), which is consistent with the potentially greater oncogenic dependency on FLT3 in this patient population [ 7 ] In the frontline treatment setting, gilteritinib in combination with chemotherapy has also shown favorable anti-leukemic responses, with a composite CR of ~80% and a 70% mutational clearance of FLT3-ITD found in a Phase I study [ 9 ].
1
—
—